Skip to main content
. 2012 Apr 17;2012:976921. doi: 10.1155/2012/976921

Figure 2.

Figure 2

Cumulative risk of the primary endpoint. The primary endpoint was a composite of death, graft loss, everolimus discontinuation and rejection.